FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has approved a niraparib regimen for patients with metastatic castration-sensitive prostate cancer (CSPC) who have a specific genetic mutation, BRCA2+. This approval is for a specific patient population with this condition. The niraparib regimen has been cleared for use in treating this type of cancer.